Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment

Glioblastoma’s (GBM) aggressive growth is driven by redundant activation of a myriad of signaling pathways and genomic alterations in tyrosine kinase receptors, such as epidermal growth factor receptor (EGFR), which is altered in over 50% of cases. Single agents targeting EGFR have not proven effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidorov, Maxim, Dighe, Pratiksha, Woo, Rinette W. L., Rodriguez-Brotons, Aida, Chen, Michelle, Ice, Ryan J., Vaquero, Edith, Jian, Damon, Desprez, Pierre-Yves, Nosrati, Mehdi, Galvez, Leah, Leng, Lewis, Dickinson, Lawrence, Kashani-Sabet, Mohammed, McAllister, Sean David, Soroceanu, Liliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954001/
https://www.ncbi.nlm.nih.gov/pubmed/36831214
http://dx.doi.org/10.3390/cells12040547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954001/
https://www.ncbi.nlm.nih.gov/pubmed/36831214
http://dx.doi.org/10.3390/cells12040547

Ejemplares similares